Innate Pharma (NASDAQ:IPHA) Stock Rating Upgraded by BTIG Research

Innate Pharma (NASDAQ:IPHA) was upgraded by equities research analysts at BTIG Research to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Innate Pharma in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $5.00.

Innate Pharma Price Performance

NASDAQ:IPHA opened at $1.50 on Wednesday. The company has a 50-day moving average of $1.71 and a 200-day moving average of $1.86. Innate Pharma has a 52 week low of $1.40 and a 52 week high of $2.63.

Institutional Investors Weigh In On Innate Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC acquired a new stake in Innate Pharma in the 4th quarter valued at about $36,000. OLD Mission Capital LLC acquired a new position in shares of Innate Pharma during the fourth quarter worth approximately $50,000. Finally, Jane Street Group LLC bought a new stake in shares of Innate Pharma during the fourth quarter valued at approximately $162,000. Institutional investors and hedge funds own 0.16% of the company’s stock.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.